CAMBRIDGE, Mass., March 17, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that it will be reporting on the chemistry leading to the discovery of its novel Hedgehog signaling pathway inhibitor, IPI-926, during the 237th American Chemical Society (ACS) National Meeting & Exposition, being held in Salt Lake City, Utah from March 22 through March 26, 2009.
